RPRX Dec 2022 40.000 put
| Previous close | 3.9700 |
| Open | 3.9700 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 40.00 |
| Expiry date | 2022-12-16 |
| Day's range | 3.9700 - 3.9700 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
- Simply Wall St.
What Kind Of Shareholders Hold The Majority In Royalty Pharma plc's (NASDAQ:RPRX) Shares?
A look at the shareholders of Royalty Pharma plc ( NASDAQ:RPRX ) can tell us which group is most powerful. Institutions...
- GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based m
- GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of bio
